Western University

Scholarship@Western
Digitized Theses

Digitized Special Collections

2011

THE ROLE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN
RECEPTOR ALPHA IN CHONDROCYTE DIFFERENTIATION
Ryan Isaac Mark Perlus

Follow this and additional works at: https://ir.lib.uwo.ca/digitizedtheses

Recommended Citation
Perlus, Ryan Isaac Mark, "THE ROLE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR
ALPHA IN CHONDROCYTE DIFFERENTIATION" (2011). Digitized Theses. 3586.
https://ir.lib.uwo.ca/digitizedtheses/3586

This Thesis is brought to you for free and open access by the Digitized Special Collections at
Scholarship@Western. It has been accepted for inclusion in Digitized Theses by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

THE ROLE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN
RECEPTOR ALPHA IN CHONDROCYTE DIFFERENTIATION

(Spine Title: The Role of RORa in Chondrocyte Differentiation)
(Thesis Format: Monograph)

By

Ryan Isaac Mark Perlus

Graduate Program in Physiology
I

A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science

School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Ryan Perlus 2011

CERTIFICATE OF EXAMINATION
Supervisors

Examiners

Dr. Frank Beier (primary supervisor)

Dr. Tim Régnault

Dr. Nathalie Berube (co-supervisor)
Dr. Rommel Tirona
Supervisory Committee
Dr. Fred Possmyer
Dr. Dean Betts (GSR)

Dr. Daniel Hardy

The thesis by
Ryan Isaac Mark Perlus
entitled:
The Role of Retinoic Acid Receptor-Related Orphan Receptor Alpha in Cartilage
Development
is accepted in partial fulfillment of the
requirements for the degree of
Masters of Science

Date

_______________________

_________________________________
Chair of the Thesis Examination Board

n

ABSTRACT
Endochondral bone formation is regulated by transcription factors and signaling
molecules. The retinoic acid receptor-related orphan receptor alpha, RORa, is involved
in tissue differentiation. RORa gene expression is upregulated during chondrocyte
hypertrophy.

Cholesterol, a RORa ligand, promotes chondrocyte hypertrophy and

stimulates expression o f lipid metabolism genes. My objective was to examine the role of
RORa during chondrocyte differentiation and in the regulation of lipid metabolism genes.
Treatment of organ cultures with T0901317, a RORa inverse agonist, resulted in
growth impairment, decreased hypertrophic zone length and delayed chondrocyte cell
cycle exit. In micromass culture T0901317 treatment reduced chondrocyte differentiation
and expression of hypertrophic differentiation markers. Lpl, a putative target of RORa,
showed decreased expression upon T0901317 treatment in vitro. RORa overexpression
in ATDC5 cells decreased Lpl expression.
Overall, T0901317 treatment affects chondrocyte hypertrophy. This suggests that
RORa is important for chondrocyte hypertrophy, potentially through control o f lipid
metabolism genes.

KEYWORDS: Chondrocytes, chondrocyte differentiation, chondrocyte hypertrophy,
micromass culture, RORa, lipid metabolism
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CHAPTER ONE

LITERATURE REVIEW
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1.1 Biology of Skeletal Development
The skeletal system serves as the basis for all human locomotion. Skeletal
development is a tightly regulated process and its disruption can lead to numerous
skeletal malformations and diseases including chondrodysplasias and osteoarthritis. Bone
formation can take place through two distinct mechanisms; intramembranous ossification
and endochondral ossification.

Intramembranous ossification is described by the

formation of bone directly from mesenchymal precursor cells (Opperman 2000; Street,
Bao et al. 2002; Kronenberg 2003). This process occurs in bones such as the flat bones of
the skull and the mandible. Endochondral ossification, on the other hand, involves bone
development through a cartilage intermediate.
1.1.1 Endochondral Ossification
The majority o f our bones are formed through the process of endochondral
ossification.

Here, mature bone is formed from a cartilage intermediate that is

subsequently replaced by bone tissue and marrow (Stanton, Underhill et al. 2003; Beier
2005). This process is tightly regulated by a vast number of transcription factors and
signaling molecules.
1.1.2 Chondrogenesis
Endochondral

ossification

begins

with

the

formation

of

mesenchymal

condensations; clusters o f cells that adhere through the expressions of adhesion
molecules.

The cells in the center o f the condensations undergo chondrogenic

differentiation (Kronenberg 2003).

Specifically, these central cells convert into pre

chondrocytes and begin to express early cartilage markers while simultaneously, turning
off expression of mesenchymal and condensation markers (Lefebvre, Li et al. 1998).
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While the cells in the middle o f the aggregates differentiate into chondrocytes, the cells in
the periphery flatten and elongate to become what is known as the perichondrium (Figure
1.1) (Kronenberg 2003). In humans, these condensations can be found at 6.5 weeks of
gestations and in mice at 10.5 days o f embryonic development (Ballock and O'Keefe
2003).
1.1.3 Chondrocyte Differentiation
Once committed to the chondrogenic pathway, chondrocytes undergo a variety of
further maturation steps involving proliferation and hypertrophy in the spatial context of
the growth plate.

Growth plates are located at either end of the bone and control

longitudinal growth. The growth plate is organized into three well-defined zones; resting,
proliferative, and hypertrophic. From the end o f the bone to the center the first zone of the
growth plate is known as the resting zone (Figure 1.2). This zone can be classified
according to its cell morphology where chondrocytes are small, round, and surrounded by
a vast quantity o f extracellular matrix rich in type II collagen, proteoglycans such as
aggrecan and cross-linking proteins (Beier 2005).

Next to the resting zone is the

proliferative zone which is characterized by chondrocytes that are discoidal in shape and
display a columnar organization (Figure 1.2) (Beier 2005). These cells undergo rapid cell
division. Once division is completed, they exit the cell cycle and become prehypertrophic
as they increase their size compared to their proliferative precursors (Hunziker 1994);
however, they are still smaller in volume compared to the next zone and final portion of
the growth plate, the hypertrophic zone.

4

Figure 1.1 Overview of Chondrogenesis
Mesenchymal cells begin to form condensations and eventually undergo
chondrogenic differentiation. Cells in the middle of the aggregates begin to express
cartilage specific markers while cells in the periphery flatten and elongate to form the
perichondrium. Chondrocytes then proliferate and differentiate to form the cartilage
anlagen.

Cartilage
Anlagen

Mesenchymal Cell
•

t

Chondrocyte
Perichondrium
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1.1.4 Hypertrophie Chondrocytes and Mineralization
Hypertrophie

chondrocytes are

responsible for many

crucial actions in

endochondral ossification and are considered to be a master regulator o f bone growth.
Chondrocytes in the hypertrophic zone are much larger in volume and have a cuboidal
shape (Beier 2005). The formation o f bone itself occurs when hypertrophic chondrocytes
undergo apoptosis. At this time, the hypertrophic cells synthesize and release specific
markers such as osteopontin, matrix metalloproteinase-9 (MMP9), vascular endothelial
growth factor (VEGF), type X collagen, and matrix metalloproteinase-13 (MMP13)
(Hojo, Ohba et al. 2010).

The secretion o f VEGF recruits blood vessels that are

accompanied by osteoclasts to resorb the specialized extracellular matrix that is distinct
from the neighboring proliferating cartilage (Lanske, Karaplis et al. 1996; Gerber, Vu et
al. 1999).

At the same time, mesenchymal cells in the periosteum differentiate into

osteoblasts, form the bone collar, and synthesize a bone-specific extracellular matrix.
Additional osteoblast precursors differentiate into osteoblasts and replace the cartilage
template with bone. This process initiates the formation o f the primary ossification center
(Figure 1.2).

1.2 Molecular Control of Chondrocyte Differentiation
1.2.1 Sex Determining Region Y Box Family (Sox) 5 , 6 , 9
Chondrogenesis involves a complex and tightly regulated series of events that is
controlled by variety of transcription factors. The members of the SRY (sex determining
region Y) box family (Sox), specifically Sox9, L-Sox5 and Sox6, play

7

Figure 1.2 Endochondral Ossification
Chondrocytes present in the cartilage anlagen further differentiate into three distinct
zones; resting, proliferative, and hypertrophic. Before hypertrophic chondrocytes
undergo apoptosis, these cells synthesize specific matrix components and growth
factors that promote vascular invasion. The appearance of the vasculature is
accompanied by osteoclasts to resorb bone. The cartilage matrix left behind by
hypertrophic chondrocytes that under apoptosis provides a scaffold for osteoblasts to
synthesize a bone specific matrix, forming the Primary Ossification center. At this
time, mesenchymal cells in the periosteum differentiate into osteoblasts to form the
bone collar. In the distal ends o f the bone, chondrocytes undergo terminal
chondrocyte differentiation, attract blood vessels and initiate the secondary
ossification center.
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C artilage
Anlagen

Resting Zone
Proliferative Zone

Hypertrophic Zone
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dominant roles in this process (Lefebvre, Li et al. 1998).

The role of Sox9 in

chondrogenesis was originally recognized through mutations in the gene that caused a
severe skeletal disease called Campomelic Dysplasia (CD) in humans (Foster 1995). It
has subsequently been found that inactivation o f Sox9 in limb bud mesenchyme results in
the complete absence of condensations and consequently, formation o f the cartilage
anlagen (Akiyama, Chaboissier et al. 2002). Furthermore, the relationship and interaction
between Sox9, L-Sox5, and Sox6 has been thoroughly investigated. It has been found
that when Sox9 expression was inactivated in cartilage by using a Collagen 2-Cre
transgene, there was no expression of L-Sox5 and Sox6 (Akiyama, Chaboissier et al.
2002). This suggests that Sox9 plays a vital role in regulating the expression of L-Sox5
and Sox6. Furthermore, in L-Sox5 and Sox6 knockout mice, typical pre-chondrogenic
condensations formed which indicates that these transcription factors are not needed for
the commitment o f mesenchymal cells to the cartilage-forming lineage (Lefebvre, Li et al.
1998).

That being said, once committed, typical chondrocytes did not form and also

failed to proliferate in the absence of L-Sox5 and Sox6, signifying the importance of
these two transcription factors in chondrocyte maturation (Lefebvre, Li et al. 1998).
Upon interaction, Sox9, L-Sox5 and Sox6 cooperate with each other to stimulate the
expression of type II collagen and other cartilage markers such as aggrecan (O'Keefe,
Puzas et al. 1994; Zhao, Eberspaecher et al. 1997).
Type II collagen is the major extracellular matrix component o f cartilage,
constituting up to sixty percent o f the total protein content (Ng, Wheatley et al. 1997).
The collagen II protein in mouse is encoded by the Col2al gene and its expression is
considered to be one of the hallmarks o f chondrogenesis (O'Keefe, Puzas et al. 1994; Ng,
Wheatley et al. 1997; Zhao, Eberspaecher et al. 1997).

It is evident that there is
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coexpression and a tight regulation of both the Sox9 and Col2al genes and Sox9 protein in
the differentiation o f chondrocytes (Ng, Wheatley et al. 1997). Both Sox9 and Col2al are
highly expressed in cartilaginous tissue until chondrocytes undergo hypertrophy and
mineralization occurs (Ng, Wheatley et al. 1997).
1.2.1 p57-kip2
Cell proliferation is controlled by the cell cycle machinery and in particular by the
activity o f cyclin-dependent kinases (Beier 2005).

Cell cycle exit and onset of

prehypertrophic differentiation o f chondrocytes are controlled by p57, a cyclin dependent
kinase inhibitor that functions to inhibit all G l/S phase cyclin dependent kinases (Zhang,
Liegeois et al. 1997).

In the skeletal system, p57 is expressed at moderate levels in

resting chondrocytes, low levels in proliferating chondrocytes, and very high levels in the
prehypertrophic zone (Zhang, Liegeois et al. 1997). In vivo analysis has showed that p57
knockout mice display shorter, thicker bones that have reduced hypertrophic zones
(Zhang, Liegeois et al. 1997).

Thus, p57 null mice show delayed chondrocyte

differentiation and postponed cell cycle exit.
1.2.2

The

Indian

Hedgehog/Parathyroid Hormone-Related

Protein Negative

Feedback Loop

Indian hedgehog (Ihh) is a member of the hedgehog family of secreted ligands and
is synthesized by prehypertrophic and hypertrophic chondrocytes (Kronenberg 2003).
Ihh regulates the progression o f the cell cycle and stimulates the expression of
parathyroid hormone-related protein (PTHrP). PTHrP is a peptide that is secreted by both
proliferating chondrocytes and the perichondrial cells. PTHrP signaling is required to
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keep chondrocytes in the proliferative pool by inhibiting the onset of hypertrophic
differentiation (St-Jacques, Hammerschmidt et al. 1999). An increase in chondrocyte
hypertrophy is accompanied by an increase in Ihh/PTHrP signaling.

This triggers a

negative feedback loop, which ultimately prevents additional chondrocytes from exiting
the cell cycle, and differentiating into hypertrophic chondrocytes thus preserving the
proliferative pool (Vortkamp, Lee et al. 1996; Kobayashi, Chung et al. 2002).
Subsequently, Ihh and PTHrP levels will decrease and terminal differentiation will
continue. As such, the length of proliferating columns and ultimately, the growth of the
cartilage growth plate is tightly regulated by the Ihh-PTHrP negative feedback loop.
1.2.3 Runx2
Runx2, formerly known as Cbfal, is a member of the family of transcription factors
containing a runt-domain. Its role in skeletal development was discovered when Runx2
knockout mice failed to form osteoblasts and therefore did not undergo ossification
(Komori, Yagi et al. 1997).

Runx2 is highly expressed in prehypertrophic and

hypertrophic chondrocytes, perichondrial cells, and osteoblasts (Kronenberg 2003). A
dominant negative form of Runx2 inhibited chondrocyte hypertrophy (Hojo, Ohba et al.
2010). Similar results were seen in Runx2 knockout mice.

As such, it has been

established that Runx2 induces chondrogenic differentiation and hypertrophy.

1.3 Disorders of Cartilage
1.3.1 Chondrodysplasias
Skeletal dysplasias are a group of genetic disorders characterized by severe
impairment of bone growth (Yasoda, Kitamura et al. 2009). Although individually each
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dysplasia is considered to be rare, together this diverse group of disorders affects a large
number o f individuals and causes severe morbidity and mortality (Superti-Furga, Bonafe
et al. 2001). Chondrodysplasia is a subset of skeletal dysplasia caused by genetic defects
affecting chondrogenesis and cartilage development (Matsui 2010). There are over 150
different forms o f chondrodysplasias (Spranger 1992). These diseases are characterized
by disordered cartilage development and bone formation resulting in dwarfism and poor
bone quality (Schwartz and Domowicz 2002). Campomelic dysplasia (CD) is one type of
chondrodysplasia that is caused by mutations in Sox9. The most obvious feature of CD is
congenital bowing and angulation o f the long bones which is often found combined with
other skeletal abnormalities and defects in cartilage formation (Foster, DominguezSteglich et al. 1994). Another example o f a chondrodysplasia is Type II Collagenopathy.
This disease is a result o f mutations in the gene for type II collagen (Spranger,
Winterpacht et al. 1994). There are many forms o f this disease and severity can vary
among patients. Some might experience moderate forms of Type II Collagenopathy such
as dwarfism while for others the disease may be lethal (Spranger, Winterpacht et al.
1994). There are also forms o f chondrodysplasias that are a result from mutations in
other collagen components such as genes encoding type IX collagen and type X collagen,
to name a few (Olsen, Reginato et al. 2000).
1.3.2 Osteoarthritis
Osteoarthritis (OA), the most common joint disease, can lead to joint pain and
dysfunction (Buckwalter and Martin 2006). It is found in more than a third of people
over 45 years old and in more than 60% of people over the age o f 65 (Buckwalter and
Mankin 1998; Buckwalter, Martin et al. 2000).

Symptoms of OA can vary from a
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sensation o f occasional joint stiffness and intermittent pain to permanent loss o f motion
and constant deep pain (Buckwalter and Mankin 1998; Poole 1999; Buckwalter, Martin et
al. 2000). OA is characterized by joint degeneration, and may include degradation and
loss o f articular cartilage, remodeling and sclerosis of subchondral bone, as well as
osteophyte formation (Buckwalter and Mankin 1998; Buckwalter, Martin et al. 2000).
The pathophysiology o f OA remains poorly understood however, as the disease appears
to be caused by a combination o f biological, mechanical, and genetic factors (Buckwalter
and Martin 2006). The primary mechanism of cartilage degeneration however, appears to
be the inability o f chondrocytes to maintain a constant balance between cartilage
synthesis and degradation, resulting in extracellular matrix catabolism (Aigner, Sachse et
al. 2006).
During endochondral ossification, chondrocytes are extremely dynamic, but,
articular chondrocytes found in synovial joints are much more static (Aigner, Kurz et al.
2002; Dreier 2010). In OA however, articular chondrocytes have been found to behave
more like growth plate chondrocytes and undergo hypertrophy (Aigner, Kurz et al. 2002;
Dreier 2010). When this process occurs, these articular chondrocytes begin to alter their
expression profiles and act like hypertrophic chondrocytes.

They begin to expression

metalloproteinases and alkaline phosphatase and this alteration is thought to contribute to
OA (Aigner, Kurz et al. 2002; Dreier 2010). Importantly, mouse mutants that show
delayed hypertrophic differentiation are protected from surgically-induced OA (Appleton,
Pitelka et al. 2007; Fu, Wang et al. 2011). Thus, any mechanisms that promote
chondrocyte hypertrophy during development are potential drug targets for the treatment
of OA.
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1.4 Nuclear Receptors
A great number of biological responses to steroid hormones and other lipophilic
substances are mediated through the interaction o f these molecules with their respective
intracellular nuclear receptors. There are three well defined categories of the nuclear
receptor family: steroid hormone receptors, thyroid/retinoid/vitamin D receptors, and
peroxisome proliferator activated receptors (Kumar and Thompson 1999). The majority
o f nuclear receptors, however, have not been linked with a known ligand and have
consequently been identified as nuclear orphan receptors (Kumar and Thompson 1999).
1.4.1 Nuclear Receptor Structure
All members o f the nuclear receptor superfamily share one major feature, a DNA binding
domain (DBD) located at the amino terminal which is crucial for the recognition of
specific DNA sequences and protein:protein interactions.

Another highly preserved

region o f nuclear receptors is the ligand binding domain (LBD) located at the carboxy
terminal end which is important for hormone binding, protein:protein interactions, and
additional transactivation activity (Giguere 1999; Kumar and Thompson 1999). Other
distinct areas of typical nuclear receptors are their hinge regions and modulator domains,
both serving a specific function (Figure 1.3A). Most nuclear receptors are constitutively
nuclear and often bound to DNA in the absence of their ligand (Giguere 1999).
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Figure 1.3 RORor Structure and Function
A) Schematic structure of the various mouse RORcr isoforms (arl and a4). The
transcription activation function 1 (AF1) domain, DNA binding domain, hinge
region, ligand binding domain (LBD), and transcription activation function 2 (AF2)
domain are indicated. The numbers on the right refer to the total number o f amino
acids in each RORor isoform. B) Mechanism of action of RORcr. RORa binds as a
monomer to ROREs. RORa interacts with coactivators or corepressors to enhance or
suppress gene transcription.
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1.4,2 Nuclear Receptor Function
All nuclear receptors function by regulating transcription, with or without a
ligand.

Transcriptional control can be achieved through a variety of mechanisms

involving direct interaction of the receptor with specific DNA sequences, with a variety
of proteins, or both (Kumar and Thompson 1999). Nuclear receptors attach to DNA
binding sites called Response Elements (RE) which are short patterned DNA sequences
o f specific nucleotides (Figure 1.3B) (Kumar and Thompson 1999). Nuclear receptors
can act as both strong activators and repressors o f gene expression (Chen and Evans
1995; Horlein, Naar et al. 1995). In many instances, nuclear receptors interact with coregulatory proteins in order to modulate transcription o f their target genes (Figure 1.3B)
(Giguere 1999).

In the presence of a ligand, co-regulatory proteins will act as co

activators and recruit additional proteins to enhance transcription.

Conversely, co-

regulatory proteins behave as co-repressors when a nuclear receptor is in its unliganded
form (Weston, Hoffman et al. 2003).

With an ever-increasing body of research, the

nuclear receptor superfamily has been found to provide organisms with a means to
directly control expression in response to a wide range of developmental and
physiological processes.

1.4.3 Nuclear Receptors in Endochondral Ossification
1.4.3.1 Vitamin D Receptor
Vitamin D is required for normal calcium and bone homeostasis. This hormone
functions by activating its receptor, the vitamin D receptor (VDR).

The VDR is

ubiquitously expressed and is highly involved in the regulation o f calcium absorption in
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the intestine and reabsorption in the kidney (Bouillon, Carmeliet et al. 2008). Activation
o f the VDR relies on the binding of its ligand 1,25-dihydroxyvitamin D 3 (l,25-(OH)2D)
and the formation o f a heterodimer with all isoforms of another nuclear receptor, the
retinoid X receptor. In VDR knockout mice, there is no skeletal phenotype at birth. At
weaning, however, VDR null mice are growth retarted and show multiple skeletal defects
(Li, Pirro et al. 1997; Yoshizawa, Handa et al. 1997). At this age, longitudinal growth of
long bones is diminished and there is disorganization o f growth plates with impaired
mineralization o f hypertrophic chondrocytes (Li, Pirro et al. 1997; Yoshizawa, Handa et
al. 1997; Erben, Soegiarto et al. 2002). The resting and proliferative chondrocytes and
the expression of typical markers o f chondrocyte differentiation appear normal however
there is a drastic decrease in hypertrophic chondrocyte apoptosis. VDRs function to
regulate bone development by inducing expression of paracrine factors such as VEGF,
which leads to increased vascular invasion, and increased osteoclast number (Bouillon,
Carmeliet et al. 2008).
1.4.3.2 Thyroid Hormone Receptor
Thyroid hormone receptors (TR) are located in the nucleus and act as hormoneactivated transcription factors. There are a variety of isoforms of TR however, only three,
T R al, TRa2, and TR pi, have been identified during endochondral bone growth (Bassett
and Williams 2003). All three isoforms are synthesized in the resting and proliferative
zones but not in the hypertrophic zone (Stevens, Hasserjian et al. 2000). Upon activation,
TRs primarily form heterodimers with the retinoid X receptor but they also have the
capability o f forming homodimers. In mouse models using TRa knockout mice, there is
an overall delay in growth plate maturation and decreased mineralization (Bassett and
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Williams 2003). In TR(3 null mice, growth plates appear to be narrow which is also
accompanied by amplified primary and secondary ossification (Bassett, O'Shea et al.
2007). Triiodothyronine (T 3 ), a thyroid hormone, inhibits chondrocyte proliferation while
simultaneously promoting hypertrophic chondrocyte differentiation (Miura, Tanaka et al.
2002 ).
1.4.3.3 Peroxisome Proliferator-Activated Receptor Gamma
There are three forms o f the peroxisome proliferator-activated receptor (PPAR):
PPARa, PPAR 8 , and PPARy. All PPARs form heterodimers with the retinoid X receptor
and bind to peroxisome proliferator response elements (PPRE) in the promoter regions of
target genes (Shao, Wang et al. 2005). PPARs are known as key regulators of many
physiological processes, mainly adipogenesis and lipid metabolism.

In the cartilage

growth plate, while transcripts for all three forms are present, only PPARy protein is
detectable. PPARy activation through treatment with a synthetic ligand and through a
pharmacological agonist results in the blockade of T 3 -induced terminal differentiation as
well as increased apoptosis (Shao, Wang et al. 2005; Stanton, Li et al. 2010).

1.4.3.4 Retinoic Acid Receptor
Retinoic acid receptors (RAR) are the major receptors for retinoic acid (RA), a
metabolite of vitamin A. The RAR family has three members, a, P, and y, each with their
own set o f isoforms. Both RARa and RARy are expressed throughout limb mesenchyme
with RARa expression downregulated upon chondrocyte differentiation (Weston,
Hoffman et al. 2003). RARy, on the other hand, is expressed throughout chondrocyte
differentiation and upregulated just prior to hypertrophy (Koyama, Golden et al. 1999).
Surprisingly, in RARa, -p, and -y knockout mice, there are no noticeable skeletal defects
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(Lohnes, Kastner et al. 1993; Lufkin, Lohnes et al. 1993; Ghyselinck, Dupe et al. 1997).
Despite the lack of a phenotype, there are dramatic skeletal defects in the developing limb
when ectopic expression of a constitutively active RAR prevents mesenchymal
condensations from undergoing chondrocyte differentiation (Weston, Rosen et al. 2000;
Weston, Chandraratna et al. 2002).

When mesenchymal cells that have completed

chondrogenesis are treated with RAR antagonists, there is an induction of Sox9
expression and activity (Weston, Chandraratna et al. 2002). The roles of RARs extend
beyond chondrogenesis.

RARs are known to be major regulators of chondrocyte

hypertrophy and mineralization (Weston, Hoffman et al. 2003). Overall, a loss of retinoid
signaling is accompanied by an induction o f chondrogenesis and a delay in chondrocyte
differentiation. It is important to note that corepressors typically interact with unliganded
forms o f the retinoid receptors and coactivators typically interact when the ligand is
present (Weston, Hoffman et al. 2003).
1.4.4 Nuclear Orphan Receptors
Throughout the investigation o f nuclear receptors and their functions, many
receptors have been identified without any known ligands. As such, these receptors were
referred to as nuclear orphan receptors (Giguere 1999).

Due to the wide variety of

nuclear orphan receptors, a classification system was developed where they were
organized into seven groups according to the molecular phylogeny (Laudet 1997). Each
group was then divided into families and each receptor within a family was identified
with a Greek letter (Giguere 1999). Most nuclear orphan receptors are structurally similar
to other nuclear receptors in that they have a highly recognizable LBD. The presence of
the LBD is a strong indicator that all orphan receptors possess the ability to bind to a
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specific ligand (Giguere 1999).

To date, there are over 40 different nuclear orphan

receptors.

Studying them has resulted in the discovery o f novel hormone response

systems.

Many nuclear orphan receptors and their ligands have been show to be

associated with known diseases such as diabetes, atherosclerosis, and cancer.

Thus,

nuclear orphan receptors have opened new therapeutic avenues for the management of
various diseases and demonstrated that they are excellent targets for drug development
(Giguere 1999).

1.5 Retinoid-Related Orphan Receptors
The increasing body o f knowledge about nuclear receptors and their involvement in
many physiological processes has resulted in the identification o f additional nuclear
orphan receptors. The retinoid-related orphan receptor (ROR) subfamily is one class of
nuclear orphan receptors that has been studied in depth. There are three different types of
RORs, the retinoic acid receptor-related orphan receptor alpha (RORa), beta (-0) and
gamma (-y).

The first ROR, RORa, was discovered in the early 1990s based on its

sequence similarities with the retinoic acid receptor (RAR) and the retinoid X receptor
(RXR) (Giguere, Tini et al. 1994). Each ROR gene generates several isoforms that differ
only in their amino-terminus (Giguere, Tini et al. 1994; Hamilton, Frankel et al. 1996).

1.5.1 RO Ra Isoforms and Structure
RORa encodes four different isoforms known as RORa 1-4, with all four being
detected in humans but only isoforms a l and a4 being detected in mouse (Jetten,
Kurebayashi et al. 2001). Most o f the isoforms exhibit a distinct pattern o f tissue-specific
expression and are involved in the regulation of a variety of physiological processes. The
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two mouse specific isoforms o f RORa encode proteins o f 523 and 468 amino acids,
respectively. RORa contains a typical nuclear receptor domain structure consisting o f
four major functional domains: an N-terminal domain followed by a highly conserved
DNA-binding domain (DBD), a hinge domain, and a C-terminal ligand-binding domain
(LBD) (Giguere 1999; Jetten, Kurebayashi et al. 2001). This nuclear orphan receptor
regulates gene transcription by binding to specific retinoid-related orphan receptor DNA
response elements (ROREs), consisting o f the consensus RGGTCA m otif preceded by an
A/T rich sequence (Giguere, Tini et al. 1994; Giguere 1999; Jetten, Kurebayashi et al.
2001). RORa binds to its RORE as a monomer and does not form heterodimers (Giguere,
Tini et al. 1994; Giguere 1999; Jetten, Kurebayashi et al. 2001). When bound to their
RORE, all four isoforms o f RORa constitutively recruit co-activators which results in
transcription o f their target genes (Atkins, Hu et al. 1999)
1.5.2 RORa Ligands
When the RORs were discovered, there were no known ligands for RORa.
Recently, cholesterol, 7-dehydrocholesterol, and cholesterol sulfate were identified as
RORa ligands (Kallen, Schlaeppi et al. 2002; Bitsch, Aichholz et al. 2003; Kallen,
Schlaeppi et al. 2004). They were found to bind to RORa in a reversible manner and to
enhance the RORE-dependent transcriptional activation by RORa. As such, it has been
suggested that RORa may function as an important regulator of lipid metabolism.

1.5.3 Mouse Models of RORa Function
A variety o f mouse models have been used to study the function o f RORa.
Interestingly however, RORa null mice exhibit an identical phenotype to that caused by a
spontaneous mutation found in homozygous staggerer mice (Sg) (Hamilton, Frankel et al.
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1996). This mutation produces a dominant negative RORa that results in a functional
knockout phenotype. Specifically, the mutation is due to a 122bp deletion in the RORa
gene resulting in the removal o f the start o f the ligand binding domain causing a frame
shift and a premature stop codon (Hamilton, Frankel et al. 1996). Sg mice exhibit many
abnormalities, many o f them found in the brain. These mice show symptoms o f ataxia
and cerebellar dysfunction, which is characterized by fewer Purkinje cells and a loss of
cerebellar granule cells (Hamilton, Frankel et al. 1996; Steinmayr, Andre et al. 1998). In
addition, Sg mice have a susceptibility to atherosclerosis, hypo-a-lipoproteinemia,
vascular dysfunction, muscular irregularities, osteoporosis, severe immune abnormalities
and display abnormal blood lipid profiles with lower circulating plasma levels o f high
density lipoprotein C (HDL-C) and plasma triglycerides (Hamilton, Frankel et al. 1996;
Steinmayr, Andre et al. 1998). Sg mice have also been found to have thinner long bones,
reduced bone diameter, and are osteopenic compared to their wild type littermates
(Meyer, Kneissel et al. 2000). In agreement with the characterized Sg mice phenotypes, it
has been shown that RORa is expressed in a wide variety o f tissues including the testis,
kidneys, adipose tissue, liver, skeletal muscle, skin, thymus, lungs, and perhaps most
abundantly in the cerebellum (Mamontova, Seguret-Mace et al. 1998; Jetten, Kurebayashi
et al.

2 0 0 1

).

1.5.4 RO Ra and Lipid Metabolism
As a result o f the staggerer phenotype displaying hypo-a-lipoproteinemia and lower
levels o f total plasma cholesterol, high density lipoprotein (HDL), and triglycerides
(Hamilton, Frankel et al. 1996; Steinmayr, Andre et al. 1998), it was suggested that
RORa plays an important role in lipid metabolism. In fact, RORa is now considered to
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have an emerging and increasing role in regulating lipid metabolism in a multitude of
tissues. The expression o f fatty acid binding protein 3 (Fabp3), which is involved in lipid
and fatty acid uptake, and o f lipoprotein lipase (Lpt), which is involved in triglyceride
hydrolysis, was reduced in C 2 C 1 2 skeletal muscle cells expressing a dominant-negative
RORa (Lau, Nixon et al. 2004).

Studies have also been performed by analyzing

expression o f putative down stream targets o f RORa in the liver (Fitzsimmons, Lau et al.
2011). RORa controls the genetic programs involved in phase I and phase II metabolism,
that regulate cholesterol homeostasis. For example, oxysterol 7a-hydroxylase (Cyp7bl)
encodes an enzyme that regulates cholesterol homeostasis and has been identified as a
RORa target gene (Kang, Angers et al. 2007). The isoform RORal has also been shown
to interact directly with the mouse ApoA-1 gene promoter (Vu-Dac, Gervois et al. 1997).
Recent investigations have proposed links between RORa and expression o f the hepatic
hormone FGF21 that has a number o f ROREs within its promoter region (Wang, Solt et
al. 2010). FGF21 has been recognized to being associated with stimulation o f fatty acid
oxidation in the liver (Wang, Solt et al. 2010).

This suggests that RORa regulates

expression of genes involved in lipid absorption, (3-oxidation, cholesterol efflux, and
energy expenditure in a variety o f tissues. Furthermore, RORa has been identified as a
promising therapeutic target in the treatment o f obesity, type II diabetes, dyslipidemia,
metabolic syndrome, and atherosclerosis (Lau, Nixon et al. 2004).

1.5.5 RO Ra in Endochondral Ossification
It has been found that RORa plays an important role in cartilage development.
Staggerer mice display slower skeletal growth and delayed hypertrophic differentiation of
chondrocytes (Tacchino et al, in prep).

When three separate models o f chondrocyte
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hypertrophy were compared, RORa was one o f the few genes that was upregulated in all
models.

Thus RORa has been suggested to be a marker o f chondrocyte hypertrophy

(Woods, James et al. 2009).

1.5.6 RO Ra Pharmacological Agents
Only one non-specific pharmacological agent has been used in vitro to investigate
the physiological role o f RORa (Kumar, Solt et al. 2010).

The synthetic ligand,

T0901317, was originally used as a liver X receptor (LXR) agonist however, recently it
was found to act as an inverse agonist o f RORa. T0901317 is the first potent inhibitor for
RORa and RORy (Kumar, Solt et al. 2010). The pharmacological effects o f T0901317
have been characterized in detail with much o f its activity attributed to LXRa and LXR0
activation (Michael, Schkeryantz et al. 2005). T0901317 was found to directly bind to
RORa and RORy resulting in a modification o f the receptor’s ability to interact with
transcriptional co-activator proteins (Kumar, Solt et al. 2010). Unfortunately, it has been
found that in addition to acting as a LXR agonist, T0901317 also activated the famesoid
X receptor (Houck, Borchert et al. 2004) and the pregnane X receptor (Mitro, Vargas et
al. 2007).

Due to the lack o f specificity o f this pharmacological agent there is great

difficulty interpreting results obtained with this compound in vitro and in vivo.

1.6 Lipid Metabolism in Endochondral Ossification
In 1982, Kirkpatrick et al. (Kirkpatrick, Mohr et al. 1982) proved that chondrocytes
contain lipid droplets.

Since then very little research has been done to elucidate the

relationship between chondrocytes, specifically chondrocyte differentiation, and lipid
metabolism. Recently, it has been shown that there is a relationship between the nuclear
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receptor PPARy2 and chondrocyte lipid metabolism (Stanton, Li et al. 2010). This study
showed that during differentiation, chondrocytes increase expression o f Lpl and Fabp4
(Stanton, Li et al. 2010). Lpl is involved in the hydrolysis o f lipoprotein triglycerides into
free fatty acids and is responsible for the uptake o f free fatty acids while Fabp4 facilities
uptake o f long chain fatty acids and low density lipoproteins. This increase in Lpl and
Fabp4 is accompanied by an increase in PPARy2 gene expression. Moreover, cholesterol
itself has been proven to promote endochondral bone growth and chondrocyte
hypertrophy in vitro and to stimulate chondrocyte expression o f genes linked to lipid
metabolism, such as Fabp4, Lpl, and Pdk.4 (Woods, James et al. 2009). Since RORa is a
receptor for cholesterol, it is possible that it plays a key role in the control o f these genes
in chondrocytes.

1.7 In Vitro Models Used to Study Chondrocytes
1.7.1 The ATDC5 Cell Line
The pre-chondrogenc cell line, ATDC5, has been established as an appropriate
model to study chondrogenesis (Shukunami, Shigeno et al. 1996). Other cell lines such
as RCJ3.1 and CFK2 have been used to study skeletal development but they are isolated
from fetal calvariae, cells that undergo intramembranous ossification, and therefore are
not an ideal model to study the endochondral pathway (Shukunami, Shigeno et al. 1996).
Originally derived from AT805 mouse embryonal carcinoma (EC) cells, ATDC5 cells
assume a fibroblastic shape when they are cultured to form a monolayer (Shukunami,
Shigeno et al. 1996). The advantage o f the ATDC5 cell line is that they can go through
the entire pathway o f chondrocyte differentiation. These cells proliferate at a high rate
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until replication terminates as a result o f contact inhibition.

Insulin supplementation

however, induces these cells to undergo chondrogenesis, chondrocyte differentiation, and
matrix mineralization (Shukunami, Shigeno et al. 1996; Shukunami, Ishizeki et al. 1997).
When ATDC5 cells undergo chondrogenesis, cells in the center of the monolayer
continue to replicate forming cellular aggregates that are indicative o f cartilaginous
nodules. These cells produce an extracellular matrix rich in proteoglycans and type II
collagen. At later stages, ATDC5 cells undergo hypertrophy, which is associated with an
increase in type X collagen gene expression, an increase in alkaline phosphatase activity,
and mineralization (Shukunami, Ishizeki et al. 1997).
1.7.2 Murine Micromass Culture System
Although the ATDC5 cell line is a convenient and frequently used model to study
chondrogenesis and chondrocyte differentiation in vitro, there are other systems that are
thought to more closely resemble the actual endochondral pathway. One such system is
the use o f limb bud mesoderm in what is known as the micromass culture system. Here,
forelimbs and hindlimbs o f embryonic day 11.5 (El 1.5) mouse embryos are dissected and
enzymatically digested. Mesenchymal cells are subsequently extracted and plated in a
high density micromass culture which allows the mesenchymal cells to preferentially
undergo chondrogenesis (Ahrens, Solursh et al. 1977). Specifically, mesenchymal cells
within the micromass form aggregates, which then differentiate into chondrocytes. As
they stabilize and proliferate, they produce an extracellular matrix. Overall, the process
o f chondrocyte differentiation in micromass culture closely follows the progression of
limb mesenchyme maturation in vivo (Cash, Bock et al. 1997).
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Previous studies have shown that cell density is a crucial factor to allow for
chondrogenesis to occur in the micromass cultures (Ahrens, Solursh et al. 1977). At the
optimal cell density of 2 x

1 0 5

cells per mass, pre-cartilagenous condensations are said to

first appear after two days in culture with cartilage nodules forming after three days
(Cash, Bock et al. 1997).

Supplementing these cultures with ascorbic acid and beta

glycerophosphate favours chondrocyte maturation and matrix mineralization, which is
said to occur at approximately day 9 o f culture (Weston, Rosen et al. 2000).
1.7.3 Tibia Organ Culture System
Previous studies in our lab have used a tibia organ culture system where tibiae are
dissected from E l 5.5 mice and cultured for six days (Agoston, Khan et al. 2007). This in
vitro approach is used primarily to determine bone growth in the absence o f any
endocrine regulation. The day o f tibiae dissection is considered to be experimental day
zero, as the tissues are allowed to recover from dissection overnight in distinct organ
culture media.

Bone length measurements are taken on days 1 and

6

with results

expressed as a change in length relative to day 1. After the culture period is complete,
tibiae can be fixed, sectioned, and analyzed for growth plate cell architecture,
immunohistochemistry, immunofluorescence, and many other protocols (Agoston, Khan
et al. 2007).

1.8 Hypothesis and Overall Objectives
The important role o f retinoic acid receptor-related orphan receptor alpha is
becoming increasingly evident in many biological tissues and physiological processes.
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The relevance o f this nuclear orphan receptor in chondrogenesis, chondrocyte
differentiation, and endochondral bone growth however, has yet to be investigated. The
studies described in this thesis will provide valuable insight into chondrocyte physiology
during skeletal development and the pathogenesis o f many skeletal diseases. They will
ultimately contribute to improved understanding o f complex molecular pathways that take
place during bone development and hopefully lead to improved treatments of many
skeletal malformations.
1.8.1 Hypothesis: RORa Promotes Expression of Lipid Metabolism Genes During
Chondrocyte Differentiation
1.8.2 Objective One: Examine the role o f RORa during chondrocyte differentiation and
skeletal development in vitro
1.8.3 Objective Two: Examine the regulation of lipid metabolism genes and proteins by
RORa in vitro

CHAPTER TWO

MATERIALS AND METHODS
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2.1 Materials
Timed pregnant CD1 mice were purchased from Charles River Laboratories (St.
Constant, Quebec, Canada). Unless otherwise stated, cell culture and organ culture media
components were purchased from Sigma and Invitrogen. The RORa inverse agonist,
T0901317, was purchased from Sigma.

The expression vectors for mouse RORa,

pCMV 6 empty expression vector, and RORa mouse shRNA were purchased from
Origene (Rockville, MD).

Hoechst 3342 nuclear acid stain was purchased from

MolecularProbes. Antibodies against Lipoprotein Lipase (catalogue number ab21356),
RORa (catalogue number ab60134), and Myc tag (catalogue number ab9106) were
purchased from Abeam (Cambridge, MA). The antibody against p57 (catalogue number
sc-8298) was purchased from Sigma.

2.2 Methods
2.2.1 Murine Micromass Cultures
Micromass cultures were prepared as described (Ahrens, Solursh et al. 1977;
Cash, Bock et al. 1997; Weston, Rosen et al. 2000; Stanton, Sabari et al. 2004) with
minor modifications. Forelimbs and hindlimbs o f up to 20 litters o f E l 1.5 CD1 mouse
embryos were dissected in Puck’s Saline A buffer (PSA). The isolated limb buds were
digested in 10 mg/ml dispase (Roche Molecular Biochemicals, Indianoapolis, IN)
solution containing 10% fetal bovine serum (FBS)/PSA for 1.5-2 hours at 37°C and
shaken at 120 rpm.

Once the tissue was fully digested, the enzymatic reaction was

neutralized with 2:3 Dulbecco’s Modified Eagles Medium (DMEM): F12 media
containing 10% FBS, 0.25% Pennicilin (10,000 units/ml)/Steptomycin (10,000 pg/ml),
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and 0.25% L-glutamine (200mM). Digested tissue was ultimately passed through a 40pm
cell strainer (Falcon, Lincoln Park, NJ) to explicitly extract cells.

The cells were

centrifuged for 5 minutes at 23°C at 1000 rpm, then resuspended in DMEM: F12 media
containing 10% FBS, 0.25% Pennicilin/Steptomycin, and 0.25% glutamine. Cells were
counted using a hemocytometer (Hausser Scientific Partnership, Horsham, PA, Catalogue
number 3200), briefly centrifuged, resuspended at a final concentration o f 2.5 X I0 7
cell/ml and plated in eight 10 pi droplets into a six well NUNC delta surface cell culture
plate (Nalge Nunc International, Rochester, NY, Catalogue number 140675). Cells were
allowed to adhere to the plates by incubating for 1 hour at 37°C and 5% CO 2 .
Subsequently,

2ml

o f 2:3

DMEM:F12

media

containing

10%

FBS,

0.25%

Pennicilin/Steptomycin, and 0.25% glutamine was added to the wells. Micromasses were
cultured for a period o f 12 days with media changed and supplemented with 50 pg/ml
ascorbic acid (Sigma) and 1 mM beta-glycerol phosphate (Sigma) each day to
differentiate the cells into chondrocytes (Stanton, Sabari et al. 2004). Media was also
supplemented every 24 hours with dimethylsufoxide (DMSO) or 20 pM T0901317
(dissolved in DMSO).
2.2.2 ATDC5 Cell Culture and Generation of Stable Transfectants
The

teratocarcinoma-derived

cell

line,

ATDC5,

chondrogenesis in vitro (Shukunami, Shigeno et al. 1996).

was

used

to

examine

The ATDC5 cell line is

prechondrogenic and chondrogenesis can be induced by supplementation with Insulintransferrin-sodium selenite media (Shukunami, Shigeno et al. 1996). Cells were cultured
in 47.5% DMEM, 47.5% F12, 5% FBS, 0.25% glutamine, and 0.25% Penicillin
Steptomycin.

Twenty-four hours post seeding, cells were treated with 1% Insulin-
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transferrin-sodium selenite media (Sigma) as described (Wang, Woods et al. 2004).
Media was changed every two days up to day fifteen o f culture. For generation o f stable
transfectants, ATDC5 cells were cultured and transfected as described (Wang, Woods et
al. 2004). Cells were plated at a density o f 2 X 104 cells/ml per well in six-well tissue
culture plates.

Once the cells reached 50-80% confluency, they were individually

transfected with expression vectors for mouse RORa (Origene, Rockville, MD), empty
expression vector pCMV 6 Entry (Origene, Rockville, MD), RORa Mouse shRNA
(Origene, Rockville, MD), and HuSH shRNA RFP cloning vector (Origene, Rockville,
MD). Pools o f cells transfected with RORa expression vector or pCMV 6 Entry were
selected with 800 mg/ml Geneticin, and pools o f cells transfected with RORa Mouse
shRNA were selected with 5 ug/ml Puromycin. ATDC5 cells and stable transfectants
were cultured for a period o f 15 days with media changed every 48 hours.
2.2.3 Staining Methods
Micromass cultures were stained for chondrogenic differentiation with Alcian
Blue (Sigma), which stains for glycosaminoglycan production. Cells were washed with
phosphate-buffered saline (PBS), fixed for 1 hour in a 10% formalin solution and then
washed again with PBS. Alcian Blue 8 Gx was added to the cells and allowed to incubate
overnight at room temperature. The following day excess stain was removed and the
cells were rinsed with 70% ethanol and air-dried before visualization (Stanton, Sabari et
al. 2004).

Following visualization, Alcian Blue stained micromass cultures were

incubated in 500 pi o f

6

M Guanidine hydrochloride overnight to exact the stain, as

described (Shioi, McMullen et al. 2002).

Absorbance o f Alcian Blue staining was

measured using a Satire Tecan Microplate Reader at 620 nm.

Terminal chondrocyte
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differentiation was visualized by staining for alkaline phosphatase (ALP) activity as
described (Stanton, Sabari et al. 2004). Cells were washed with PBS, fixed for 1 hour in
a 10% formalin solution, and washed again double distilled water for 15 minutes. A
solution containing 0.1 mg/ml naphthol AS-MX phosphate (Sigma), 0.5% N,Ndimethylformamide, 2 mM MgCL, and 0.6 mg/ml Red Violet LB salt (Sigma) in 0.1 M
Tris/HCl (pH 8.3) was added to the cells, and the micromass cultures were incubated in a
dark environment for 45 minutes. After the incubation time, excess stain was removed
and the cells were washed with double distilled water, then air-dried until visualization.
To visualize calcium deposition and mineralization, Von Kossa staining was used. Cells
were washed with PBS and fixed with 10% formalin solution. Micromasses were stained
with ALP as above before staining with 2.5% silver nitrate solution for 30 minutes. Cells
were then washed with water and allowed to air-dry before visualization (Stanton, Sabari
et al. 2004). All images were taken using a Leica EC3 microscope and Leica Application
Suite V3 software.
2.2.4 DNA Content Measurement of Micromass Cultures using Hoechst Staining
Quantification of DNA content in micromass cultures was performed using the
UV-excitable DNA stain Hoechst 3342 at a concentration of 5 pg/ml.

Micromass

cultures plated in parallel to the previous discussed stains were cultured, treated, and
fixed as previously mentioned. Cultures were then washed with PBS and incubated with
Hoechst DNA dye for 15 minutes at 37°C. Following the incubation, cells were washed
with PBS and incubated in a 1:1 trypsinxollagenase solution for 30 minutes. The cells
were then centrifuged at 1000 rpm for 5 minutes and resuspended in culture media.
Resuspended cells were used to measure DNA content using a fluorometer (Model RF-
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M2004, Photon Technology International, London, ON) with excitation at 350 nm and
emission at 450 nm. Data from 3 independent trials was analyzed using Felix32 software.
2.2.5 Protein Isolation and Western Blotting
Micromass cultures were washed with PBS and incubated in Radiolmmuno
Precipitation Assay (RIPA) lysis buffer for 30 minutes on ice. Cell lysates were then
sonicated and collected after a 30 minute centrifugation at 4°C at 12, 000 x g. Protein
was subsequently quantified by bicinchoninic acid (BCA) assay (Sigma) according to
manufacturer’s recommendations. To analyze protein levels, protein was diluted to 25
ng/pl, combined with double distilled water, NuPAGE Sample Reducing Agent (lOx)
(Invitrogen), NuPAGE LDS Sample Buffer (4x) (Invitrogen) and run on a NuPAGE 412% Bis-Tris Gel (Invitrogen). Protein was then transferred to an Immun-Blot PVDF
Membrane (Bio-Rad, Hercules, CA, USA). Nonspecific protein sites were blocked using
a 5% non fat milk powder in lx TBST. The membrane was incubated overnight at 4°C in
mouse monoclonal primary antibody to lipoprotein lipase IgG (Abeam), washed three
times in lx TBST for

8

minutes, and then incubated for one hour in horse radish

peroxidase (HRP) conjugated-secondary antibody.
washes in lx TBST were performed.

An additional three eight minute

Signal was detected using ECL Plus Western

Blotting Detection System (GE Healthcare, Baie d’Urfe, QB) and visualization was
performed using a Konica Minolta SRX-101A developer.
2.2.6 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction
In the ATDC5 cell culture experiments, total RNA was isolated on days 3, 6 , 9,
12, and 15 days using an RNeasy kit (Qiagen), according to manufacturer’s instructions.
In the micromass culture experiments, total RNA was isolated on days 3,

6

, 9 and 12
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using an RNeasy kit (Qiagen), according to manufacturer’s instructions.

RNA was

quantified using a ND-1000 nanodrop. After concentrations were obtained, RNA was
diluted to 40 ng/pl for use in Quantitative Real-Time Polymerase Chain Reaction (qPCR).
A 14 pi mixture o f specific target primers and probes generated from Applied Biosystems
TaqMan Assays-on-Demand and a Taqman one-step mastermix kit (Applied Biosystems)
was combined with 1 pi RNA for a final volume o f 15 pi. The ABI Prism 7900 HT
sequence detector (PerkinElmer Life Sciences) was used to detect amplified target
sequences. All analyses were performed in triplicate for each time point, and data are a
combination o f a minimum of three independent trials.
were

calculated

relative

to

the

internal

control

Real-Time expression values
glyceraldehyde-3-phosphate-

dehydrogenase (Gapdh) using the relative quantification AACt analysis.
2.2.7 Organ Culture
Following euthanasia, E l 5.5 mouse tibiae were dissected and placed into twenty
four well dishes containing sterile Organ Culture Media containing a-MEM, ascorbic
acid,

beta-glycerophosphate,

bovine

serum

albumin,

glutamine,

and

Penicillin/Streptomycin on ice as described (Agoston, Khan et al. 2007; Ulici, Hoenselaar
et al. 2009). Tibiae were dissected using dissection forceps and a Zeiss Stereo Zoom
Microscope Stemi SV6 . Following dissections, tibiae were washed with sterile PBS.
Fresh sterile organ culture media was then added to the plates and incubated at 37°C and
5% CO 2 . The following day, bone length was measured using an eyepiece ruler on the
Zeiss Stereo Zoom Microscope Stemi SV 6 , and an inverse agonist in varying
concentrations was added to the culture (DMSO vehicle or 1 ,5 , 10 or 20 pM T0901317
(Sigma)). Medium including treatments were changed every other day, and after

6

days
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tibiae were measured again. Bone growth was determined by the difference in length
between day

6

and day 1. One subset o f tissues were then fixed in 4% paraformaldehyde

overnight.

These bones were labeled using 2% Mercurochrome (Alpha, catalogue

number 1011965) and sent to the Molecular Pathology Core Facility, Robarts Research
Institute, for tissue processing, paraffin embedding, and sectioning at a depth o f 5 pm.
Another subset o f bones were incubated overnight in 70% ethanol followed by an
overnight incubation in acetone. Bones were then incubated for two hours in Alcian
Blue/Alizarian Red solution.
2.2.8 Histology and Immunohistochemistry
Paraffin embedded sections were dewaxed in Xylene for

8

minutes and 5 minutes,

respectively, followed by rehydration in 2 x 100% ethanol, 95% ethanol, and 70 %
ethanol for 2 minutes each. Histological Staining was performed using a Safranin O and
Fast Green for 25 minutes and 7 minutes, respectively.

Slides were then dehydrated and

mounted using Xylene based mounting media. Immunohistochemistry was performed as
previously discussed (Laron 2008) with minor modifications. Sections were incubated in
3% H 2 O 2 for 15 minutes at room temperature to block endogenous peroxidases. Antigen
retrieval was then performed by incubating sections in lOmM Sodium Citrate solution at
pH6.0 at 95°C for 15 minutes. Sections were blocked with 5% goat serum and incubated
with primary antibodies overnight at 4°C.

The following day, sections were washed

twice for 5 minutes in PBS and incubated for 1 hour in secondary antibody conjugated to
HRP.

Visualization was then performed using Liquid DAB+ Substrate Chromagen

System (DAKO, catalogue number K3468). Slides were then counterstained with methyl
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green solution.

To analyze the images a Leica DM1000 microscope and Leica

Application Suite V3 software were used.
2.2.9 Statistical Analysis
All data collected were from at least 3 independent trials. Data were expressed as
mean ± SEM, and p values under 0.05 were considered significant (*).

Statistical

significance was determined with t-test or two way ANOVA followed by a post-hoc
Bonferroni test using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA).

CHAPTER THREE

RESULTS
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3.1 Treatment with T0901317 Results in Decreased Longitudinal Growth
In order to assess the influence o f RORa inhibition on bone growth, I isolated
tibiae from E l 5.5 mice.

After extracting the tibiae, I cultured them for six days as

described (Agoston, Khan et al. 2007; Ulici, Hoenselaar et al. 2009; Woods, James et al.
2009) with slight modifications. I measured the tibiae on day 1 and day 6 . Bones were
treated with either DMSO vehicle or the RORa inverse agonist T0901317 (in different
concentrations) on day 1 and then every subsequent 48 hours. Data shows there is a
significant decrease in bone growth between bones treated with DMSO vehicle and 20pM
T0901317 (Figure 3.1 A). Furthermore, a subset o f the tibiae was stained with alcian
blue/alizarin red to visualize cartilage (shown in blue) and the mineralized portion o f the
bone (shown in red). It can be seen that the overall length and the length o f both the
distal cartilage are reduced in the 20 pM T0901317 treated tibiae compared to the DMSO
vehicle (Figure 3.IB). Together, this insinuates that RORa is crucial for proper skeletal
growth.

3.2 Tibiae Treated with T0901317 Display Shortened Hypertrophic Zones
After I observed a decrease in bone growth with T0901317 treatment, I wanted
to analyze how growth plate architecture was altered in this condition.

Tibiae were

cultured for a period o f 6 days in T0901317 (20 pM) or DMSO vehicle and then sent for
embedding in paraffin and sectioning (Robarts Research Institute, Molecular Pathology,
London, Ontario, Canada). In order to assess growth plate organization, I performed
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Figure 3.1 Treatment with T0901317 Results in Decreased Longitudinal Growth
E l 5.5 tibiae were grown and cultured for a period o f 6 days and treated every 48
hours with medium containing DMSO vehicle, lpM T0901317, 5pM T0901317,
lOpM T0901317, or 20pM T0901317. Tibiae were measured on day 1 o f culture and
then at the end of day

6

for assessment o f longitudinal growth. A) Tibiae treated with

20pM T0901317 had a significant reduction in growth compared to the control. Data
shown are an average o f 6 independent trials, ± SEM, * p<0.05. B) A subset o f the
tibiae was stained with alcian blue/alizarin red to visualize cartilage (shown in blue)
and the mineralized portion o f the bone (shown in red). Overall length and the length
o f the growth plates are reduced in the 20 pM T0901317 treated tibiae compared to
the DMSO vehicle.
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histological analyses using 0.1% Safranin 0/0.02% fast green staining. The growth plate
organization did not appear to be altered drastically with treatment; however, tibiae
treated with T0901317 displayed shorter hypertrophic zones (Figure 3.2A). Furthermore,
growth plate zone measurements were taken by a blinded observer in order to quantify
my observations. Due to the difficulty o f identifying a clear border between the resting
and proliferative zones, we combined these zones into one measurement and compared to
the length o f the hypertrophic zone and total growth plate length. It can be seen that the
quantitative data agree with my qualitative observations. There is a significant reduction
in both the hypertrophic zone and total growth plate length in T0901317 treated tibiae
compared to the vehicle control (Figure 3.2B).

3.3 p57 Protein Expression in Growth Plate is Decreased in RORa Inverse Agonist
Treated Bones
Since I saw a reduction in hypertrophic zone length in tibia treated with 20 pM
T0901317, I wanted to examine what stage of chondrocyte differentiation was being
affected by the treatment. I chose to study specific molecular markers of chondrocyte
differentiation and examine them in tibiae cultured for

6

days with T0901317 or DMSO

using immunohistochemistry. I analyzed the cyclin-dependent protein kinase inhibitor,
p57 (Kip2), which is a marker o f cell cycle exit and has been characterized as a marker of
the transition o f proliferative chondrocytes into prehypertrophic chondrocytes (Zhang,
Liégeois et al. 1997). In control bones I saw the expected staining for p57, with strongest
expression at the transition from proliferating to prehypertrophic zones (Figure 3.3A).
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Figure 3.2 Tibiae Treated with T0901317 Display Shortened Hypertrophic Zones
After

6

days in culture with DMSO vehicle or 20|jM T0901317, tibiae were

embedded in paraffin and sectioned. Growth plates were stained with safranin-o and
fast green solution for visualization o f growth plate organization and cell
morphology. A) Growth plates treated with T0901317 displayed shortened
hypertrophic zones (shown by arrows). Data shown are representative o f 6
independent trials. B) Growth plate zones were measured from E l 5.5 tibiae treated
with DMSO vehicle or 20 pM T0901317. Treatment with T0901317 resulted in a
significant decrease in total growth plate length and hypertrophic zone length. n= 6 ,
p<0.05.
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When treated with 20pM T0901317, p57 protein expression is decreased in the
prehypertrophic zone (Figure 3.3A). I quantified the immunohistochemical staining using
Leica Application Suite software and in agreement with the qualitative staining, there is a
significant reduction in p57 staining in T0901317 treated growth plates (Figure 3.3B).
This suggests that there is a delay in cell cycle exit and onset o f prehypertrophic
chondrocyte differentiation.

3.4 PCNA Protein Expression in Growth Plate is Decreased in RORo Inverse
Agonist Treated Bones
If chondrocytes are being prevented from undergoing hypertrophy, there should
be an increase in the proliferative pool. Proliferating cell nuclear antigen (PCNA) is a
member o f the DNA sliding clamp family o f proteins that assist in DNA
replication (Kelman and O'Donnell 1995) and is a marker o f chondrocyte proliferation. I
performed immunohistochemistry on the E l 5.5 tibiae that were cultured for
DMSO vehicle or 20 pM T0901317.

6

days with a

Surprisingly, there was no increase in PCNA

staining in the T0901317 treated bones compared to the vehicle controls (Figure 3.4).
Conversely, there seemed to be a decrease in the fraction o f cells expressing PCNA in the
treated bones (Figure 3.4) and as such, the effect o f T0901317 extends to chondrocyte
proliferation in addition to chondrocyte hypertrophy.
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Figure 3.3 p57 Protein Expression in Growth Plates is Decreased in RORff
Inverse Agonist Treated Bones
Tibiae were isolated from E l 5.5 mouse embryos, grown, and cultured for a period of
6 days. Tibiae were treated every 48 hours with medium containing DMSO vehicle
or 20

|j M

T0901317. Tissues were fixed and prepared for histology.

A) Immunohistochemistry was performed with a p57 primary antibody followed by
secondary antibody and visualization with the substrate DAB (dark brown staining).
Extracellular matrix was counterstained with methyl green. Representative images
show p57 protein levels highest in the prehypertrophic zone o f control section;
however, with treatment with RORa inverse agonist, p57 protein expression is
decreased in this region. n=6. B) Immunohistochemical staining was quantified using
Leica Application Suite software. There is a significant reduction in p57 staining in
the T0901317 treated growth plates. n=5.
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Figure 3.4 PCNA Protein Expression in Growth Plate is Decreased in RORcr
Inverse Agonist Treated Bones
Immunohistochemistry was performed on the E l 5.5 tibiae that were cultured for 6
days with a DMSO vehicle or 20 pM T0901317. Tissues were fixed and prepared for
histology. There was a decrease in protein expression (dark brown staining) in the
T0901317 treat bones compared to the DMSO controls. n=3.
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3.5 RORa Inhibition Results in Decreased Glycosaminoglycan Production
I next wanted to study the role o f RORa during chondrocyte differentiation in
vitro. One model that has been widely applied to study these processes is the use o f limb
bud mesoderm micromass cultures. In this system, forelimbs and hindlimbs o f E l 1.5
mouse embryos are dissected and enzymatically digested. Once isolated, mesenchymal
cells are plated in high density 10 pi droplets known as micromass cultures.

In this

configuration, mesenchymal cells preferentially undergo chondrogenesis (Ahrens,
Solursh et al. 1977). These cells were cultured and grown for 12 days. They were fed
with

specific

culture

media

and

supplemented

with

ascorbic

acid

and beta

glycerophosphate every 24 hours. It is important to note, that chondrocyte maturation
and matrix mineralization has been proven to start at approximately 9 days o f culture
(Weston, Rosen et al. 2000).

I treated the micromass cultures with either a DMSO

vehicle or RORa inverse agonist every day starting on day 3 to allow natural
chondrogenic differentiation in the initial culture period. I stained the micromass cultures
at days 6, 9, and 12 with alcian blue for glycosaminoglycan content.

As expected,

staining intensity increased over time in control cultures (Figure 3.5A). The intensity of
this staining and o f this differentiation marker is reduced with T0901317 treatment
(Figure 3.5A). I then quantified the alcian blue content o f the micromasses by using a
spectrophotometer at 620 nm after extraction with 6M Guanidine hydrochloride.
Treatment with T0901317 resulted in significant decrease in absorbance levels (Figure
3.5B), thus correlating with the qualitative observations previously made and showing
that inhibition o f RORa function results in a decrease in markers o f early chondrocyte
differentiation.
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Figure 3.5 RORor Inhibition Results in Decreased Glycosaminoglycan
Production in Micromass Culture
Mouse embryonic mesenchymal limb bud cells were plated in micromass cultures and
grown for 12 days with either DMSO vehicle or R O Ra inverse agonist (T0901317),
starting on day 3. They were stained after 6, 9, and 12 days with Alcian blue for
glycosaminoglycan content. A) The intensity o f this staining and o f this
differentiation marker is reduced with T0901317 treatment. B) After 6, 9, and 12 days
the Alcian blue content of the micromasses was quantified after extraction with 6 M
Guanidine hydrochloride using spectrophotometry at 620 nm. Treatment with
T0901317 resulted in decreased absorbance levels. n=6, p<0.05.
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3.6 Treatment with RORa Inverse Agonist Results in Reduced Chondrocyte
Hypertrophy and Mineralization
Next, I wanted to examine if there was also an effect on later stages of
chondrocyte differentiation. I stained a subset o f micromass cultures that were grown for
12 days and treated every day starting on day 3 with either DMSO vehicle or T0901317
for alkaline phosphatase activity and von Kossa staining.

Alkaline phosphatase is a

marker o f chondrocyte hypertrophy, while von Kossa staining is a marker of
mineralization. Staining was performed on days 6, 9, and 12. In agreement with previous
data (Stanton, Sabari et al. 2004; James, Appleton et al. 2005), intensity o f staining in
control cultures increased over time for both markers. Similar to the alcian blue staining,
the intensity o f alkaline phosphatase staining was reduced in T0901317 treated
micromass cultures (Figure 3.6A). Furthermore, there was also a reduction in von Kossa
staining in the T0901317 treated cultures (Figure 3.6B). Thus, in addition to a decrease in
early chondrocyte differentiation there is also a reduction in chondrocyte hypertrophy and
mineralization. This data agrees with the results obtained from the T0901317 treated
tibiae discussed previously.

3.7 T09013I7 Does Not Affect DNA Content of Micromass Cultures
I next wanted to confirm that the RORa inverse agonist did not have toxic effects
on the micromass cultures. Another subset o f the micromasses was cultured, using the
same protocol as previously described, so I could analyze the DNA content of the
cultures. I performed this analysis on days 6, 9, and 12 days. To measure DNA content I
used a Hoechst 33342 fluorescence stain. Measurements showed that
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Figure 3.6 Treatment with RORa Inverse Agonist Results in Reduced Alkaline
Phosphatase Activity and Mineralization
Mouse embryonic mesenchymal limb bud cells were plated in micromass cultures and
grown for 12 days and treated with either DMSO vehicle or RO Ra inverse agonist
(T0901317) on day 3. They were stained after 6, 9, and 12 days for various
chondrocyte differentiation markers: A) Alkaline phosphatase activity and B) Von
Kossa for mineralization. The intensity of both these markers are reduced in the
T0901317 treated micromass cultures. n=6.
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treating the micromass cultures with T0901317 resulted in no significant changes in DNA
content (Figure 3.7).

3.8 Expression

of Chondrocyte Differentiation Markers is Decreased with

Treatment of T0901317 in Micromass Cultures
After observing decreased staining in markers o f chondrocyte differentiation, I
wanted to examine which gene expression profiles were being affected when micromass
cultures were treated with the RORa inverse agonist. Mesenchymal cells were again
dissected from forelimbs and hindlimbs o f E l 1.5 CD1 mouse embryos. The cells were
isolated, cultured, and grown in micromass cultures for 12 days. During the first 3 days,
cultures were incubated with specific media only to allow for chondrogenic
differentiation. Starting on day 3, cells were treated daily with either DMSO vehicle or
20 pM T0901317. Total RNA was extracted on days 3, 6, 9 and 12. mRNA levels were
then quantified by Real Time PCR and all relative gene expression levels were compared
to house keeping gene, Glyceraldehyde 3 phosphate dehydrogenase (Gapdh).

I first

investigated Sox9 and Col2al, which are markers o f early chondrocyte differentiation.
Relative gene expression of both markers o f early chondrocyte differentiation was
greatest at day 6 and decreased at each additional time point.

There is a significant

decrease in Sox9 expression at day 6 and day 12 in the T0901317 treated micromass
cultures compared to the DMSO vehicle (Figure 3.8A). No significance was detected at
day 9 however, the same trend is evident on this day as the other time points (Figure
3.8A). Furthermore, although no statistical significance was found in Col2al expression
between the T0901317 treated and DMSO vehicle micromass cultures,

i

I
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Figure 3.7 T0901317 Does Not Affect DNA Content of Micromass Cultures
Mouse embryonic mesenchymal limb bud cells were plated in micromass cultures and
grown for 12 days and treated with either DMSO vehicle or RORa inverse agonist
(T0901317) on day 3. To measure DNA content, Hoechst 33342 fluorescence stain
was used. This was performed on days 3, 6, 9, and 12. Measurements showed that
treating the micromass cultures with T0901317 did not result in significant changes in
DNA content. n=3.

Hoechst Stain
Fluorescence Intensity
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there is also a decreasing trend at each time point in the treated cells (Figure 3.8B). Thus,
both Sox9 and Col2al expression suggest that there is a decrease in early chondrocyte
differentiation with treatment o f the RORa inverse agonist.
To elucidate the role o f T0901317 treatment on chondrocyte hypertrophy, I
analyzed the relative gene expression o f Runx2 (Figure 3.9A) and alkaline phosphatase
(Figure 3.9B).

The gene expression profiles o f both Runx2 and alkaline phosphatase

show that starting at day 9 there was a dramatic increase, which is when chondrocyte
hypertrophy begins in micromass cultures (Weston, Rosen et al. 2000). Coincidently,
there is a reduction in gene expression in T090191317 treated cultures at days 9 and 12.
This correlates with the previous histological staining data in that the RORa inverse
agonist reduces chondrocyte hypertrophy.

Lastly, I analyzed the gene expression of

M m plS (Figure 3.10A) and CollOal (Figure 3.10B), which are both markers of terminal
chondrocyte differentiation.

As anticipated, the relative gene expression o f M mpl3

significantly increased at day 12.

Uncharacteristically, CollOal expression remained

relatively constant from day 6 to day 12. There was a statistically significant reduction in
M m pl3 gene expression at day 6 and day 12 upon treatment (Figure 3.10A). In addition,
at every time point, there is a decreasing trend of CollOal gene expression in the
T0901317 treated micromass cultures compared to the DMSO vehicle (Figure 3.10B).
Combined, these results signify that the RORa inverse agonist reduces expression o f both
early and late markers o f chondrocyte differentiation.
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Figure 3.8 Early Chondrogenic Gene Expression is Decreased with Treatment of
T0901317 in Micromass Cultures
Mesenchymal cells dissected from forelimbs and hindlimbs o f E l 1.5 CD1 embryos
were plated and grown for 12 days in micromass cultures. Total RNA was extracted
on days 3, 6, 9, and 12. Cultures were treated with either DMSO vehicle or 20 pM
T0901317, starting on day 3. RNA was quantified by Real Time PCR. All relative
gene expression levels were compared to house keeping gene Gapdh transcript levels.
Relative transcript levels o f various marker genes o f early chondrocyte differentiation
such as A) Sox9 and B) Col2al in control cultures decrease with micromass
differentiation. Furthermore, there is a decrease in Sox9 expression at days 6 and 12
with T0901317 treatment. There is a decreasing trend in Col2al expression with
T0901317 treatment. n=6, p<0.05.
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Figure 3.9 Chondrocyte Hypertrophic Gene Expression is Decreased with
Treatment of T0901317 in Micromass Cultures
Mesenchymal cells dissected from forelimbs and hindlimbs o f E l 1.5 CD1 embryos
were plated and grown for 12 days in micromass cultures. Total RNA was extracted
on days 3, 6, 9, and 12. Cultures were treated with either DMSO vehicle or 20 pM
T0901317, starting on day 3. RNA was quantified by Real Time PCR. All relative
gene expression levels were compared to house keeping gene Gapdh transcript levels.
Relative gene expression o f markers of chondrocyte hypertrophy such as A) Rurvc2
and B) Alkaline Phosphatase are dramatically increased at day 9 in control cultures.
Additionally, treatment with T0901317 results in a significant decrease in both Runx2
and Alkaline Phosphatase expression at days 9 and 12. n=6, p<0.05.
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Figure 3.10 Markers of Terminal Chondrocyte Differentiation and
Mineralization Show Lower Expression upon Treatment of T0901317 in
Micromass Cultures
Mesenchymal cells dissected from forelimbs and hindlimbs o f E l 1.5 CD1 embryos
were plated and grown for 12 days in micromass cultures. Total RNA was extracted
on days 3, 6, 9, and 12. Cultures were treated with either DMSO vehicle or 20 pM
T0901317, starting on day 3. RNA was quantified by Real Time PCR. All relative
gene expression levels were compared to house keeping gene Gapdh transcript levels.
Relative gene expression o f markers of terminal chondrocyte differentiation and
mineralization such as A) M m pl3 and B) Col 10a 1 are analyzed. A) Relative gene
expression o f M m pl3 increases with chondrocyte differentiation and there is a
reduction in gene expression at days 6 and day 12 of T0901317, relative to DMSO.
B) Gene expression o f Col 10a 1 in control cultures remained relatively constant with
chondrocyte differentiation and no significant decrease was detected between control
and treated cultures. There is a decreasing trend at days 6, 9, and 12 in the T0901317
treated cultures. n=6, p<0.05.
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3.9 Relative Gene Expression of Lipid Metabolism Genes is Altered with T0901317
Treatment
Next, I was interested in determining if the receptor itself was self-regulated. As
such, I analyzed RORa gene expression in the micromass cultures as described above. In
agreement

with

earlier data,

Rora

mRNA

levels

increase

during

micromass

differentiation (Figure 3.11 A). Treatment with T0901317 resulted in no difference of
RORa gene expression (Figure 3.11 A) with peak RORa expression occurring at day 9,
which is when hypertrophy begins. In other tissues, it has been found that some lipid
metabolism genes are direct targets o f RORa. As such, I wanted to identify what effect
treatment with T0901317 was having on putative targets o f RORa.

The first gene I

analyzed was Lpl as it was found to be a direct target gene is muscle cells (Lau, Nixon et
al. 2004). In control cultures, Lpl expression increased over time in a pattern similar to
Rora (Figure 3.1 IB). Unexpectedly, I detected an increase in Lpl expression at day 6 in
the T0901317 treated cultures. However, at day 12 o f culture, Lpl gene expression in the
treated micromass cultures was decreased compared to the D M §0 vehicle (Figure
3.1 IB). Next I investigated the expression of Lipg, a water soluble lipase that catalyzes
the hydrolysis o f lipids. Gene expression o f Lipg remained relatively constant during
micromass differentiation. Surprisingly, Lipg gene expression was increased at days 9
and 12 in the treated micromasses (Figure 3.11C). I next analyzed the expression o f the
fatty acid carrier protein, fatty acid binding protein 3 (Fabp3). No significant differences
were detected in Fabp3 gene expression at any time points (Figure 3.12A). Another gene
involved in lipid metabolism is pyruvate dehydrogenase kinase
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Figure 3.11 Relative Gene Expression of Lipid Metabolism Genes is Altered with
T0901317 Treatment
Mesenchymal cells dissected from forelimbs and hindlimbs o f E l 1.5 CD1 embryos
were plated and grown for 12 days in micromass cultures. Total RNA was extracted
on days 3, 6, 9, and 12. Cultures were treated with either DMSO vehicle or 20 pM
T0901317, starting on day 3. RNA was quantified by Real Time PCR. All relative
gene expression levels were compared to house keeping gene Gapdh transcript levels.
A) Relative gene expression data shows that in micromass cultures treated with
T0901317, there is no significant difference in ROR a transcript levels compared to
control cultures. Peak expression of R O R aoccurs at day 9 o f culture. B) In control
cultures, Lpl gene expression is greatest at day 12. There is a statistically significant
increase in Lpl expression at day 6 with a significant decrease at day 12 in T0901317
treated cultures. C) Lipg relative gene expression is increased at day 9 and maintained
at day 12 in control cultures. There is a significant increase in T0901317 treated
micromass cultures at days 9 and 12. n=6, p<0.05.
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Figure 3.12 Relative Gene Expression of F abp3 and P d k 4 Genes is Unchanged
with T0901317 Treatment
Mesenchymal cells dissected from forelimbs and hindlimbs of E l 1.5 CD1 embryos
were plated and grown for 12 days in micromass cultures. Total RNA was extracted
on days 3, 6, 9, and 12. Cultures were treated with either DMSO vehicle or 20 pM
T0901317, starting on day 3. RNA was quantified by Real Time PCR. All relative
gene expression levels were compared to house keeping gene Gapdh transcript levels.
A) No difference was detected in Fabp3 gene expression with T0901317 treatment.
B) There was no significant difference in Pdk4 gene expression in treated cultures
however, there is a trend that suggests there is decreased Pdk4 expression with
treatment. n=6, p<0.05.
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isozyme 4 (Pdk4). In the control cultures, Pdk4 expression increased with micromass
differentiation.

There was no statistically significant difference detected between the

T0901317 treated micromass cultures and DMSO controls, however, there is a decreasing
trend at every time point with treatment (Figure 3.12B).

3.10 Lpl Protein Levels are Decreased at Days 9 and 12 in Micromass Cultures with
Treatment of RORa Inverse Agonist
In addition to studying the effect o f T0901317 on Lpl gene expression in
micromass cultures, I desired to investigate protein levels o f this lipid metabolism gene in
micromass cultures treated with T0901317.

Mesenchymal cells were again dissected

from forelimbs and hindlimbs of E l 1.5 CD1 mouse embryos. The cells were isolated,
cultured, and grown in micromass cultures for 12 days. During the first 3 days, cultures
were incubated with specific media only to allow for chondrogenic differentiation.
Starting on day 3, cells were treated daily with either DMSO vehicle or 20 pM T0901317.
Total protein was isolated by incubating cells in RIPA lysis buffer. Protein levels were
then analyzed using western blot. In agreement with its gene expression, Lpl protein
levels were decreased at days 9 and 12 in the T0901317 treated cells compared to the
DMSO control (Figure 3.13). This suggests that Lpl could potentially be a target gene of
RORa in cartilage.

?
i
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Figure 3.13 Lpl Protein Levels Appear Decreased at Days 9 and 12 in Micromass
Cultures with Treatment of RORff Inverse Agonist
Mesenchymal cells were dissected from forelimbs and hindlimbs o f E l 1.5 CD1
mouse embryos. The cells were isolated, cultured, and grown in micromass cultures
for 12 days. Micromasses were treated with either DMSO vehicle or 20 pM
T0901317. Total protein was isolated by incubating cells in RIPA lysis buffer.
Protein levels were analyzed using western blot. Lpl protein levels appeared to be
decreased at day 9 and 12 in the T0901317 treated cells compared to the DMSO
control. Data shown are representative from 3 independent trials.
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Figure 3.14 Lpl Protein Expression is Decreased in RORcr Inverse Agonist
Treated Bones
Tibiae were isolated from E l 5.5 mouse embryos. Tissues were fixed and prepared
for histology. Immunohistochemistry was performed with a Lpl primary antibody
followed by secondary antibody and visualization with the substrate DAB (dark
brown staining). Extracellular matrix was counterstained with methyl green.
Representative images show evidence that growth plates from tibiae treated with
T0901317 have less Lpl protein expression than the control sections. Data shown are
representative from 3 independent trials.

T0901317

Control
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3.11 Lpl Protein Expression is Decreased in RORa Inverse Agonist Treated Bones
After I found that Lpl gene expression was decreased in RORa inverse agonist
treated micromass cultures, I wanted to go back and analyze protein expression in the
tibia organ culture system previously described. In the DMSO control bones, there was
staining for Lpl in the hypertrophic zone (Figure 3.14). T0901317 treatment caused
decreased Lpl protein expression in the hypertrophic zone o f the growth plate (Figure
3.14).

3.12 Relative Gene Expression of Lpl follows a Similar Profile as Rora in ATDC5
cells
Next, I was interested in determining the gene expression profile o f RORa and
Lpl,

a

putative

downstream

target,

the

pre-chondrogenic

cell

line

ATDC5.

Chondrogenesis can be induced in ATDC5 cells by supplementation with Insulintransferrin-sodium selenite media (Shukunami, Shigeno et al. 1996). Cells were plated at
a density o f 5 X 104 cells per well in six-well culture plates. Total RNA was extracted on
days 5, 10, 15 and 20 and mRNA levels were quantified by Real Time PCR.

In

agreement with the observation that RORa is upregulated with chondrocyte hypertrophy
(Woods, James et al. 2009), there was an increase in RORa gene expression at day 15 of
culture (Figure 3.15A). I then wanted to determine the expression profile o f Lpl and if
peak expression o f Lpl followed RORa as predicted. Accordingly, Lpl gene expression
was maximally expressed at day 20 of culture (Figure 3.15B). This supports the model
that Lpl is downstream o f RORa.
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3.13 Expression of Lpl is Decreased upon Overexpression of RORo in Transfected
ATDC5 Cells
All studies previously performed in this thesis analyzed the effect of inhibition of
RORa on lipid metabolism. As such, I wanted to observe the effect of a gain-in-function
in RORa on putative downstream targets, specifically Lpl.

I generated a cell line of

stable transfectants that were transfected with a mouse RORa cDNA clone. I isolated
RNA on days 3, 6, 9, and 12 and quantified using Real Time PCR. To confirm that the
transfections were successful, I wanted to analyze the gene expression profile of RORa in
the stable transfectants. As expected, Rora gene expression was significantly increased in
the transfected cells compared to the control (Figure 3.16A).

I anticipated that, in

agreement with previous data explained in this thesis, overexpression o f RORa would
cause the gene expression o f Lpl to increase; however, this was not the case.
Unexpectedly, Lpl gene expression decreased in the transfected cells (Figure 3.16B).

3.14 Expression of Hypertrophic Differentiation Markers is Decreased upon
Overexpression of RORa in Transfected ATDC5 Cells
Continuing with the analysis RORa overexpression, I proceeded to study gene
expression o f markers o f chondrocyte hypertrophy. Employing the ATDC5 cell line of
RORa stable transfectants, I isolated RNA on days 3, 6, 9 and 12 and quantified gene
expression using real-time PCR. I analyzed the relative gene expression of Runx2 and
alkaline phosphatase. In agreement with previous data, overexpression o f RORa resulted
in an increase in relative gene expression o f both markers of hypertrophic chondrocyte
differentiation (Figure 3.17).
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Figure 3.15 Relative Gene Expression of Lpl follows a Similar Profile as RORa in
ATDC5 cells
ATDC5 cells were plated at a density o f 5 X 104 cells/well and cultured for a period
o f 20 days. Total RNA was extracted on days 5 ,1 0 ,1 5 , and 20. RNA was quantified
by Real Time PCR. All relative gene expression levels were compared to house
keeping gene Gapdh transcript levels. A) Relative RO Ra gene expression was greatest
at day 15 o f culture. B) The gene expression profile o f Lpl was similar to RORa with
peak expression at day 20 of culture. n=3, p<0.05.
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Figure 3.16 Expression of L p l is Decreased upon Overexpression of RORcr in
Transfected ATDC5 Cells
Stable transfectants overexpressing RORa were generated using a mouse RORcr
cDNA clone in ATDC5 cells. Cells were plated at a density o f 5 X I04 cells/well and
cultured for a period o f 12 days. RNA was isolated on days 3, 6, 9, and 12. RNA
was quantified using Real Time PCR. All relative gene expression levels were
compared to house keeping gene Gapdh transcript levels. A) Relative gene expression
of RO Ra in transfected cells was significantly increased compared to their controls.
B) The gene expression o f Lpl was significantly decreased on days 6 ,9 , and 12 in the
transfected cells compared to the controls. n=3, p<0.05.
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Figure 3.17 Expression of Hypertrophic Differentiation Markers is Decreased
upon Overexpression of RORcr Transfected ATDC5 Cells
Stable transfectants overexpressing RORa were generated using a mouse RORcr
cDNA clone in ATDC5 cells. Cells were plated at a density of 5 X I04 cells/well and
cultured for a period of 12 days. RNA was isolated on days 3, 6, 9, and 12. RNA
was quantified using Real Time PCR. All relative gene expression levels were
compared to house keeping gene Gapdh transcript levels. A) Relative gene expression
of alkaline phosphatase in transfected cells was significantly increased compared to
their controls at day 12. B) The gene expression o f M m pl3 was significantly
increased on days 6, 9, and 12 in the transfected cells compared to the controls. n=3,
p<0.05.
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4.1 Summary of Results
The role o f nuclear receptors in endochondral ossification is becoming increasingly
complex. To date, several nuclear receptors have been recognized as being involved in
chondrocyte differentiation, such as the vitamin D receptor, the thyroid hormone
receptors, the peroxisome proliferator-activated receptor gamma, and the retinoic acid
receptors (Miura, Tanaka et al. 2002; Weston, Hoffman et al. 2003; Bouillon, Carmeliet
et al. 2008; Stanton, Li et al. 2010). The body o f knowledge of RORa however, has not
extended to the same degree to chondrocyte differentiation.
It has previously been found that RORa plays a role in bone metabolism in vitro and
in vivo by directly modulating the expression o f a bone matrix component, bone
sialoprotein (BSP) (Meyer, Kneissel et al. 2000). This was the first study to address the
role o f RORa in the skeletal system. Recently, it has been found that staggerer (Sg) mice
(which have a loss-of-function mutation in the Rora gene) display slower skeletal growth
and delayed hypertrophic differentiation o f chondrocytes (Tacchino et al., in prep).
Moreover, three independent models of chondrocyte hypertrophy show an upregulation o f
RORa gene expression, suggesting that RORa could be a marker o f chondrocyte
hypertrophy (Woods, James et al. 2009).
The relationship between RORa function and lipid metabolism has been investigated
in skeletal muscle where RORa regulates expression o f genes involved in lipid
absorption, P-oxidation, cholesterol efflux, and energy expenditure in this tissue (Lau,
Nixon et al. 2004). Lastly, the role of lipid metabolism in endochondral ossification is
just emerging.

Studies from our laboratory have shown that during differentiation,

chondrocytes increase expression of Lpl and Fabp4 (Stanton, Li et al. 2010). Cholesterol,
a ligand for RORa, has been shown to promote endochondral bone growth and
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chondrocyte hypertrophy in vitro and to stimulate the expression of lipid metabolism
genes (Woods, James et al. 2009). Thus, I hypothesized that RORa promotes expression
o f lipid metabolism genes during chondrocyte differentiation.
To study the role of RORa on chondrocyte differentiation in vitro I used a RORa
pharmacological inverse agonist T0901317. T0901317 has been extensively used as an
LXR agonist however, it was more recently found that T0901317 directly binds to RORa,
resulting in the receptor’s ability to interact with transcriptional co-activator proteins
(Kumar, Solt et al. 2010).
My first aim was targeted at examining the effect o f T0901317 treatment on bone
growth.

Analysis o f organ culture tibiae treated with 20 pM T0901317 showed a

reduction in total bone growth.

Histological staining by SafraninO/Fast green of the

tibiae treated with 20 pM T0901317 showed a shortened hypertrophic zone. Next I
wanted to investigate the mechanism that caused the reduction in total bone growth.
Through immunohistochemistry, I observed a reduction in p57 staining in the
prehypertrophic zone o f T0901317 treated tibiae, indicating a delay in cell cycle exit. To
elucidate the role o f RORa in chondrocyte differentiation, I analyzed markers o f early
and late differentiation in micromass cultures.

Markers of early chondrocyte

differentiation such as alcian blue staining, Col2al expression, and Sox9 expression were
decreased with RORa inhibition.

Markers of chondrocyte hypertrophy and terminal

differentiation such as alkaline phosphatase activity, von Kossa staining, Runx2
expression, and M m plS expression were also decreased with T0901317 treatment,
suggesting that RORa inhibition results in a reduction o f all phases o f chondrocyte
differentiation.
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I next investigated the influence o f RORa inhibition on lipid metabolism genes.
In the micromass cultures, RORa gene expression increased with chondrocyte
differentiation with peak expression at day 9 o f culture. The gene expression of all lipid
metabolism genes analyzed increased with chondrocyte differentiation, with the exception
o f Fabp3. More importantly, expression o f Lpl, a gene already found to be a direct target
o f RORa in other tissues (Lau, Nixon et al. 2004), peaked at day 12 o f culture in control
conditions, and was increased at day 6 and reduced at day 12 in the T0901317 treated
cultures. In contrast, expression of Lipg was increased at days 9 and 12 with T0901317
treatment. There is also a decreasing trend at every time point o f Pdk4 expression with
RORa inhibition. Protein levels were also examined in the T0901317 treated micromass
cultures. There appears to be a moderate decrease in Lpl protein levels at days 9 and 12
in the T0901317 treated cultures.

Furthermore, in the tibia organ culture system

previously discussed, I found that treatment with T0901317 resulted in a reduction o f Lpl
protein expression in the hypertrophic zone.
All studies performed to this point analyzed the effect o f the inhibition o f RORa
on chondrocyte differentiation and lipid metabolism. I wanted to explore the effects o f a
gain-of-function o f RORa on these physiological processes.

Unexpectedly, stable

ovexpression o f RORa in ATDC5 cells surprisingly resulted in a decrease in Lpl gene
expression.
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4.2 Contribution and Significant Findings
4.2.1 Contribution to the Current State of Knowledge of RORa in Chondrocyte
Differentiation
Since their discovery in 1995, staggerer (Sg) mice have been thoroughly
characterized. Much o f this research has focused on the cerebellar phenotype o f Sg mice
as it has been found that Purkinje cell development in the cerebellum o f Sg mice is
originally normal but these cells are not able to differentiate and subsequently die (Vogel,
Sinclair et al. 2000). RORa has also been linked to skeletal development. It was found
that Sg mice display a bone phenotype, having thinner long bones and decreased bone
mineral density leading to their characterization as osteopenic (Meyer, Kneissel et al.
2000). Recent studies have investigated the role o f RORa in cartilage development using
Sg mice as an in vivo model o f RORa deficiency (Tacchino et al., in prep). Moreover, it
has also been found that in three independent models of chondrocyte hypertrophy, Rora
expression was upregulated (Woods, James et al. 2009). However, the molecular targets
o f RORa in cartilage development have not been elucidated.
The phenotype o f the Sg mouse however, is not limited to the cerebellum, bone,
and cartilage. These mice also display multiple lipid metabolism defects such as lower
levels o f plasma cholesterol, HDL, and triglycerides (Hamilton, Frankel et al. 1996).
Based on these findings, it was suggested that RORa also plays a role in lipid
metabolism. It has been recognized that chondrocytes contain lipid droplets (Kirkpatrick,
Mohr et al. 1982). Previous research in our lab has shown that there is also a connection
between the nuclear receptor PPARy2 and chondrocyte lipid metabolism (Stanton, Li et
al. 2010). During differentiation chondrocytes increase expression o f Lpl and Fapb4 and
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this increase is accompanied by an increase in PPARy2 expression (Stanton, Li et al.
2010). Another study from our lab has proven that cholesterol, the ligand for RORa,
promotes endochondral ossification, chondrocyte hypertrophy in vitro and stimulates the
expression o f lipid metabolism genes such as Fabp4, Lpl, and Pdk4 (Woods, James et al.
2009). The present study however, is the first in vitro approach using pharmacological
agents to elucidate the mechanism of action of RORa on lipid metabolism genes during
chondrocyte differentiation.
There is a strong body o f knowledge concerning the role of nuclear receptor
function in endochondral ossification. For example, the vitamin D receptor functions to
regulate vascular invasion and matrix mineralization (Bouillon, Carmeliet et al. 2008). In
addition to lipid metabolism, PPARy2 functions to inhibit terminal differentiation and
apoptosis (Stanton, Li et al. 2010). Retinoic acid receptors are known as major regulators
o f chondrocyte hypertrophy and mineralization (Weston, Hoffman et al. 2003).

It is

evident that nuclear receptors play an integral role in cartilage physiology.
I show for the first time the effect of the RORa inverse agonist T0901317 on
chondrocyte differentiation. The observations presented in this study suggest that RORa
plays a major role in chondrocyte hypertrophy.

I observed a thirty-three percent

reduction in the hypertrophic zone of organ culture growth plates treated with a RORa
inverse agonist, a decrease in alkaline phosphatase staining and a decrease in
hypertrophic markers in micromass cultures. The observed decrease in hypertrophic zone
length and molecular markers could be a result o f two different mechanisms. If terminal
differentiation is accelerated, hypertrophic chondrocytes could potentially undergo
apoptosis at a faster rate, thereby leaving less o f a hypertrophic pool o f cells. On the
other hand, a delay in cell cycle exit by proliferating chondrocytes would also produce a
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reduced hypertrophic zone. It should be noted that these possibilities are not mutually
exclusive, and either or both can contribute to the observed effects o f T0901317. The
observed reduction in p57 staining in T0901317 treated tibiae supports the latter theory
and suggests that treatment with T0901317 results in a delay in chondrocyte
differentiation; a finding that directly correlates with the in vivo analysis o f Sg mice
(Tacchino et al, in prep). Furthermore, this data relates to previous literature, as RORa is
known to be a regulator o f differentiation in a variety o f tissues. In the cerebellum o f Sg
mice, purkinje cells were not able to undergo differentiation (Vogel, Sinclair et al. 2000)
and in muscle tissue, RORa is important in the differentiation of myotubules (Lau,
Fitzsimmons et al. 2011).

4.2.2 Contribution to the Current State of Knowledge of RORa and Lipid
Metabolism During Endochondral Ossification
Previous studies have discovered a connection between nuclear receptors involved
in chondrocyte differentiation and lipid metabolism (Stanton, Li et al. 2010).
Furthermore, literature has implicated a common link between crucial signaling pathways
involved in chondrocyte differentiation such as the PI3K/AKT signaling pathway and
lipid metabolism pathways such as cholesterol (Ulici, James et al. 2010). In this study, I
identified a role o f the nuclear orphan receptor RORa in the regulation of lipid
metabolism genes in chondrocytes. Drawing a parallel with previous research, this study
identified a connection between RORa and Lpl, a known target of RORa in muscle tissue
(Lau, Nixon et al. 2004). Although no direct relationship could be proven, the decrease in
Lpl expression observed with T0901317 treatment agrees with the literature to this point.
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To solidify this argument, overexpression o f RORa should be accompanied by an
increase in Lpl expression. Surprisingly, I did not observe the anticipated increase in Lpl
expression. Instead, RORa overexpression yielded a decrease in Lpl expression. Nuclear
receptor function is very convoluted.

In several instances, crosstalk between nuclear

receptor pathways involves competition between receptors binding to the same response
element (Jetten, Kurebayashi et al. 2001).

This relationship has been demonstrated

between RORs and other nuclear receptors such as Rev-Erba and Rev-Erbp, which act as
transcriptional repressors. There is no evidence for such a mechanism in this instance. A
more appropriate model is the inherent ability o f numerous nuclear receptors to recruit
repressors to inhibit transcription. Typically, corepressors interact with unliganded forms
o f nuclear receptors. The retinoic acid receptors, which are the most similar receptors to
RORa, have been found to recruit co-repressor proteins in the absence o f retinoic acid,
thereby maintaining chromatin in the condensed state that causes transcriptional
repression (Weston, Hoffman et al. 2003). Because there was an exponential increase in
exogenous RORa in the transfected cells accompanied by unaltered levels o f cholesterol,
it is reasonable to predict that many of the receptors remained in this unliganded state,
thereby hindering transcription of target genes.
Other surprising observations made were the increases in Lpl expression at day 6
and Lipg expression at days 9 and 12 in T0901317 treated micromass cultures. Both
genes have been identified as targets of another nuclear receptor, LXR (Lau, Nixon et al.
2004; Norata, Ongari et al. 2005).

In addition to acting as a RORa inverse agonist,

T0901317 acts as a LXR agonist. Therefore, these unexpected results could potentially
be due to the supplementary agonistic effects o f T0901317 on LXR signaling. In this
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manner, because RORa expression does not peak until approximately day 9 of culture,
the increase o f Lpl could be due to the activation of LXR.

4.3 Limitations of Research and Future Directions
In the studies present, three different in vitro culture systems were used. In the
micromass cultures, mesenchymal cells were isolated from E l 1.5 mouse limb buds and
cultured under pro-chondrogenic conditions. They were plated at very high densities to
promote

cell-cell

interactions

and

supplemented

with

ascorbic

acid

and

0-

glycerophosphate (Weston, Rosen et al. 2000; James, Appleton et al. 2005; Stanton and
Beier 2007). Mesenchymal cells however, are pluripotent and thus have the ability to
differentiate into any mesoderm tissue such as adipose tissue, muscle tissue, bone and
cartilage (Zelzer, McLean et al. 2002).

Previous studies from our lab have found a

decrease in gene expression o f markers o f other cell types accompanied by an increase of
cartilage specific markers (James, Appleton et al. 2005). Because some of the cells on the
periphery o f the micromasses are more fibroblastic in shape, there is still the potential for
cell types other than chondrocytes to be present (James, Appleton et al. 2005).
Another cell culture system used in this study was the pre-chondrogenic cell line
ATDC5. Although the ATCD5 cell system resembles that o f primary chondrocytes, there
could be differences in gene expression between these cells and actual chondrocytes.
This serves to be a limitation o f this cell line and cell lines in general.
To analyze growth plate morphology, I used a tibia organ culture system. In this
model, tibiae are cultured in serum free media to allow for bone growth without any
endocrine functioning. Pharmacological agents can be used in this system to elucidate
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specific effects in a three-dimensional context. This system provides the opportunity to
study the effects o f a single hormone, growth factor, or in this case, nuclear receptor. It
also allows for observations to be made based on bone-specific effects. Furthermore, in
the organ culture system I was able to observe changes in specific growth plate zones, a
feature that is not possible in cell culture systems. However, it should be noted that not all
aspects controlling cartilage development (e.g. biomechanical loads and oxygen tension)
are recapitulated in this model.
In this study, the pharmacological inverse agonist T0901317 was used to study the
role o f RORa. This synthetic ligand binds to RORa, thereby limiting its ability to interact
with co-activator proteins. On other hand, the effects o f T0901317 are not specific to
RORa, a factor that cannot be ignored. T0901317 was originally used as a LXR agonist
(Michael, Schkeryantz et al. 2005).

LXR is classically known as a key regulator of

cholesterol homeostasis and therefore I cannot exclude that some o f the observed effects
o f T0901317 on chondrocyte differentiation could be due to activation o f proteins in the
LXR pathway. The use o f a RORa specific pharmacological agent in the in vitro studies
discussed in this thesis would be an ideal method to alleviate the activation o f other
related nuclear receptors. Although it is not commercially available yet, a potential agent
that would fit this criterion is the synthetic agonist SRI 078. This agent functions as a
RORa specific agonist and in fact, activates the receptor beyond its physiological level
(Wang, Kumar et al. 2010). Another approach to identify RORa-specific effects of
T0901317 was to compare drug effects to those o f RORa-specific shRNAS. I attempted
this approach using stable transfection o f ATDC5 cells with shRNA-overexpressing
plasmids, but was not able to achieve efficient knockdown o f Rora transcript levels and
correspondingly no effects on Lpl expression were observed (Suppl. Fig. 1).
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All experiments performed in this thesis attempted to describe the role of RORa in
chondrocyte differentiation through the activation o f lipid metabolism genes in vitro. To
date, the best-characterized model of RORa investigations in vivo is the Sg mouse. This
mutant however, has intrinsic complications in that skeletal phenotypes detected could be
due to endocrine limitations and mechanical restraints o f the mice themselves. To control
for these external factors, a cartilage-specific knockout mouse o f RORa would be ideal
and would also help to overcome the limitations o f the in vitro culture systems described
above. For this to be performed, a mouse with a floxed Rora allele crossed with a mouse
expressing Cre recombinase under the control o f a collagen II promoter would remove
RORa from cartilage tissue only. Our lab has developed tissue-specific knockdowns for
a variety o f other genes such as Gsk3b, Atrx, and R acl (Wang, Woods et al. 2007;
Solomon, Li et al. 2009; Ulici, Hoenselaar et al. 2009; Gillespie, Ulici et al. 2011).
Analyzing gene expression and protein profiles o f potential down stream targets
are valuable methods in identifying the roles o f nuclear receptors during chondrocyte
differentiation. To fully understand RORa’s role in cartilage physiology, direct or indirect
effects o f this transcription factors need to be distinguished.

Quantitative chromatic

immunoprécipitation (ChIP) assays would allow for the identification o f direct
downstream targets o f RORa. This would further allow us to identify the molecular basis
o f any changes observed in the cell culture or organ culture experiments.

There are

commercially available antibodies against RORa that have been previously used for ChIP
from mouse tissues (Fujieda, Bremner et al. 2009). However, in our experience they are
not specific in Western blotting, which raises questions about their suitability for ChIP.
Furthermore, ChIP should ideally be performed on primary chondrocytes but we are
limited by our ability extract enough cells for ChIP.

Rather, the stable transfectant
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ATDC5 cell line that has been produced which overexpresses the RORa gene could be
applied. The myc tag on the overexpressed RORa could also be used for ChIP as this
antibody has been used for a variety o f experiments (Nateri, Spencer-Dene et al. 2005).
One caveat o f this approach is that approximately ten-fold overexpression of this
transcription factor as observed in my study could yield non-physiological binding events.

4.4 Significance
The studies in this thesis have shown that T0901317 treatment affects chondrocyte
differentiation, in particular chondrocyte hypertrophy. My thesis suggests RORa to be an
important regulator of late chondrocyte differentiation, potentially through the regulation
o f lipid metabolism genes such as Lpl, Pdk4, and Lipg. The search for potential nuclear
receptors and their effect on the regulatory pathways o f chondrocyte differentiation
remains a challenging task. I have however, contributed to this field by suggesting that
RORa plays an integral role in chondrocyte differentiation. Ultimately, my studies have
contributed valuable insights into chondrocyte physiology during skeletal development
and potentially the pathogenesis skeletal diseases. The studies performed here contribute
to improved understanding of complex molecular pathways that occur during bone
development and will hopefully lead to improved treatments o f skeletal malformations.
Finally, due to the fact that OA articular chondrocytes undergo hypertrophy (Aigner,
Kurz et al. 2002), RORa could be implicated as a potential therapeutic target since
inhibition o f the receptor results in delayed hypertrophic differentiation. Targeting RORa
in OA therapy is not unreasonable as nuclear receptors are increasingly being investigated
as potential targets to prevent or slow the progression o f the disease (Loeser 2009).
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Ill

Supplementary Figure 1 Expression of RORa in RORcr sHRNA Transfected
ATDC5 Cells
Stable transfects silencing RORa were generated using a mouse RORcr cDNA clone
ATDC5 cells. Cells were plated at a density o f 5 X104cells/well and cultured for a
period o f 12 days. RNA was isolated on days 3, 6 , 9 , and 12. RNA was quantified
using Real Time PCR. All relative gene expression levels were compared to house
keeping gene Gapdh transcript levels. B) Relative gene expression o f RORa in
transfected cells was inconclusive compared to their controls. B) The gene
expression o f Lpl was inconclusive on days 6, 9, and 12 in the transfected cells
compared to the controls. n=3.
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